Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.

Adjuvant trastuzumab in HER2-positive breast cancer.

Collaborators (400)

Cassanello G, Fein L, Giacomi N, Korbenfeld E, Justina M, Mickievicz E, Abdi Toowoomba E, Bayliss E, Begbie S, Beith J, Chan A, Van Hazel G, Chirgwin J, Claringbold P, Clingan P, Craft P, Dalley D, De Boer R, Dewar J, Ganju V, Gauden S, Green M, Grimes D, Kannourakis G, Koczwara B, Kotasek D, Lewis C, Links M, Mccarthy N, Ransom D, Richardson G, Schwarz M, Selva-Nayagan S, Olver I, Stewart J, Sullivan A, White M, Woodward N, Young R, Dittrich C, Sevelda P, Cocquyt V, Demol J, Dirix L, Mebis J, Verhoeven D, Vermorken J, Beslija S, Ferrari BL, Lago S, Sanches SM, Anelli A, Schwartsmann G, Timcheva K, Tzekova V, Dorreen M, Dufresne J, Klimo P, Latreille J, Lopez P, Mackinnon J, Zibdawi L, Potvin C, Provencher L, Roy J, Sehdev S, Smylie M, Wilson J, Jimenez A, Rodolpho Gomez L, Sanchez O, Vargas Baéz C, Grgic M, Markulin-Grgic L, Mrsic-Krmpotic Z, Vrdoljak E, Kakouri E, Petruzelka L, Stefanek I, Vodvarka P, Vyzula R, Azim H, el-Khodary A, Padrik P, Valvere V, Bonneterre J, Vanlemmens L, Bressac C, Cals L, Campone M, Carola E, Colin P, Dalivoust P, Dutel J, Ferrero J, Namer M, Gligorov J, Guastalla J, Jaubert D, Khayat D, Levy E, Priou F, Roché H, Schaeffer F, Tournigand C, Valenza B, Vannetzel J, Baumann K, Breitbach GP, Brunnert K, Camara O, Carstensen M, Christensen B, Clemens M, Conrad B, Du Bois A, Eiermann W, Feltz-Süssenbach J, Hempel D, Henschen S, Herbstreit C, Hilfrich J, Jonat W, Keil E, Morack G, Kettner E, Kiesel L, Klare P, Kretzschmar A, Kristen P, Kunz S, Kullmer U, Kurzeja J, Souchon R, Lichtenegger W, Lürmann K, Meinerz W, Müller T, Zippel, Nestle-Krämling C, Dall P, Prell W, Reimer T, Gerber B, Scharl A, Schmidt W, Schneeweiss A, Bastert J, Schweppe K, Tessen H, Tome O, Meerpohl MG, Von Minckwitz G, Kaufman B, Wiest W, Winzer K, Wolf H, Zedelius M, Efremidis A, Georgoulias V, Kwong A, Chow L, Boer K, Baki M, Dank M, Pinter T, Szanto M, Advani S, Doval D, Gupta S, Julka P, Ranade A, Crown J, Grogan L, Janku F, Keane M, Kennedy J, Mc Caffrey J, O'Reilly S, Breathnach O, Barak F, Efrat N, Fried G, Goldberg H, Geffen D, Isacson R, Kaufman B, Rizel S, Safra T, Steiner M, Barone C, Bonetti A, Gamucci T, Gasparini G, Iaffaioli R, Marangolo M, Massacesi C, Moscietti L, Nardi M, Panetta A, Geminiani ML, Ravaioli A, Abi Gerges D, Chahine GY, Ghosn M, Saghir N, Chan C, Silva A, Valle A, Harvey V, Isaacs R, Jameson M, Czerepinska A, Karnicka-Mlodkowska H, Pienkowski T, Rolski J, Pawlicki M, Wojtukievicz M, Zaluski J, Badulescu F, Ghilezan N, Roman L, Stanculeanu D, Gutulescu N, Garin A, Gorbunova V, Semiglazov V, Koza I, Korec S, Spanik S, Matos E, Cufer T, Takac I, Beltchev E, De Bruyne R, Maart K, Jacobs CR, Moodley S, Pienaar R, Rapoport B, Slabber C, Ahn J, Kim MW, Bang Y, Choi J, Ho-Yeong L, Im Y, Sil Ro J, Adrover E, Alba E, Albiol Rodríguez S, Ales Martinez J, Alonso Romero J, Alvarez Lopez I, Aranda E, Arcusa Lanza A, Baena Canada J, Calvo Martinez L, Crespo Massieu C, Dominguez S, Florian Gerico J, Jara Sanchez C, Lobo F, Margeli Vila M, Martin M, Mel Lorenzo J, Oltra Ferrando A, Pelegri A, Fornander T, Aapro M, Chao T, Liu MC, Frikha M, Mezlini A, Aydiner A, Ozisik Y, Baltali E, Chan S, Carmichael J, Sherwin L, Wardley A, Krygier G, Rodriguez Lemes R, Abubakr Y, Adler M, Ansari R, Arena F, Beall C, Beattie J, Pluard T, Berdeaux D, Bianco A, Brufsky A, Burris H, Carroll RR, Chakrabarti A, Chitneni S, Chap L, Chowhan N, Cobb P, Diaz-Lacayo M, Hussein A, Dreisbach P, Fain J, Kerr R, Falkson C, Fesen M, Gluck S, Tang SC, Gonzalez A, Goodman J, Greenwald D, Hajdenberg J, Hoffman S, Holmes F, Hurvitz S, Jhangiani H, Jones M, Justice G, Juturi J, Kalman L, Kennedy P, Kincaid W, Klein L, Koneru K, Lange M, Laufman L, Lemon R, Limentani S, Link J, Forsthoff C, Lower E, Malamud S, Mcandrew P, Mccroskey R, Mckeen EA, Mena R, Mills K, Modiano M, Moore T, Moroose R, Moss R, Nair B, Neel J, Olopade O, Orlowski R, Page R, Patel D, Patton A, Perez A, Perkins C, Petruska P, Philip J, Polikoff J, Posada J, Young RR, Rahman Z, Rangineni R, Reich E, Reiling R, Foulke R, Rinaldi D, Robert N, Robertson P, Osborn D, Rodriguez G, Rubin P, Russell C, Saleh M, Savin M, Schleider M, Schwartzberg L, Shaffer D, Shiftan T, Silverman P, Overmoyer B, Slamon D, Smith J, Solky A, Boros L, Sparano J, Sylvester L, Tansino G, Tchekmedyian S, Tezcan H, Ulrich N, Valero V, Vargas-Cuba R, Campbell L, Vaughn C, Vogel C, Waintraub S, Wallmark J, Wierman A, Torotouglou N, Yunus F, Yost K, Zaren H, De Jongh C, Vera Gimon R.

Author information

  • 1Jonsson Comprehensive Cancer Center, University of California–Los Angeles, Los Angeles, CA 90095-1678, USA. dslamon@mednet.ucla.edu

Abstract

BACKGROUND:

Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab.

METHODS:

We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive doxorubicin and cyclophosphamide followed by docetaxel every 3 weeks (AC-T), the same regimen plus 52 weeks of trastuzumab (AC-T plus trastuzumab), or docetaxel and carboplatin plus 52 weeks of trastuzumab (TCH). The primary study end point was disease-free survival. Secondary end points were overall survival and safety.

RESULTS:

At a median follow-up of 65 months, 656 events triggered this protocol-specified analysis. The estimated disease-free survival rates at 5 years were 75% among patients receiving AC-T, 84% among those receiving AC-T plus trastuzumab, and 81% among those receiving TCH. Estimated rates of overall survival were 87%, 92%, and 91%, respectively. No significant differences in efficacy (disease-free or overall survival) were found between the two trastuzumab regimens, whereas both were superior to AC-T. The rates of congestive heart failure and cardiac dysfunction were significantly higher in the group receiving AC-T plus trastuzumab than in the TCH group (P<0.001). Eight cases of acute leukemia were reported: seven in the groups receiving the anthracycline-based regimens and one in the TCH group subsequent to receiving an anthracycline outside the study.

CONCLUSIONS:

The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. The risk-benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia. (Funded by Sanofi-Aventis and Genentech; BCIRG-006 ClinicalTrials.gov number, NCT00021255.).

Comment in

PMID:
21991949
[PubMed - indexed for MEDLINE]
PMCID:
PMC3268553
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Write to the Help Desk